Fab’entech services

Due to their immediate neutralising action, Fab’entech’s polyclonal antibodies can be used to design therapies that are well suited to the management and treatment of drug intoxications.

Fab’entech has over 12 years of expertise in the Research and Development of immunotherapies against emerging infectious diseases. Since 2009, Fab’entech has been involved in programmes intended to combat H5N1 avian influenza, the Ebola haemorrhagic fever and the Crimean-Congo haemorrhagic fever (CCHF). Fab’entech has notably developed a product against the H5N1 avian influenza (Fabenflu) and a product against Ebola under the aegis of the World Health Organisation (WHO) and with the support of the European Medicines Agency (EMA). More recently, Fab’entech has been heavily mobilised on the development and production of an anti-SARS-CoV2 treatment, the FabenCOV, which has strong neutralisation capacities on all variants.